RESOLVING THE LEDGER
RESOLVING THE LEDGER
Only one outlet has reported this event so far — you're reading it below, credited to its source. AIPROPX is tracking the web for more coverage; as additional outlets confirm it, this becomes a full multi-source story automatically.
By AIPROPX Editorial Desk · Published · Updated
One outlet is reporting this so far. AIPROPX is tracking it and will gather every additional source as it develops — the full multi-source comparison appears automatically once a second outlet confirms it.
LONDON — Half a year into taking over the job, GSK CEO Luke Miels on Tuesday laid out his plans to turn the U.K. pharma giant into a more agile company with years of growth ahead.
A key step, Miels said, will be a three-year campaign to generate 1.9 billion pounds (about $2.5 billion) in annual savings by 2029, much of which will be reinvested to advance the company’s late-stage pipeline. The company also now plans to start at least 20 Phase 3 trials this year, up from the 10 that it had disclosed at the beginning of 2026.
“We are step-by-step building a set of potential best-in-class products across our core therapy areas,” Miels said, a list that includes some newer target areas — like oncology and liver disease — as well as longtime GSK focuses like vaccines and HIV. Miels would not say Tuesday how many jobs would be cut under the savings drive.
Continue to STAT+ to read the full story…
Indexed and credited by AIPROPX. Originating outlet: STAT. Open at source →
An original, deterministic readout — composed only from the computed coverage facts on this page. No interpretation, no rating; figures only.
AIPROPX has consolidated 1 report from 1 outlet into a single canonical entry on “STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials.” Every covered outlet is based in Other.
The only timestamped report came from STAT (Jul 28, 2026, 14:11 UTC).
2 statements are carried by only one outlet within this set and are not echoed by the others.
Every figure above is a direct count of real published articles. AIPROPX indexes and compares the original reporting — it never rewrites, rates, or editorializes — and each publisher’s full article is always one click away.
Generated by AIPROPX from the source counts above. AIPROPX indexes and resolves coverage; the original publishers are credited and linked at origin in every report.
Coverage from 1 independent outlet across 1 region — each view opens on its own page.
AIPROPX — “STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials” · https://www.aipropx.com/story/5bf13cba74615f3ecf7b71460eef953f
Other events being covered across multiple sources right now.
Spider-Man: Brand New Day Reviews Are Split On If It’s One Of Spidey’s Greatest Movies Or Just More Of The Same
4 outletsAriana Grande Is Taking on Her Hackers—Once She Figures Out Who They Are
4 outletsNational Chicken Wing Day 2026 deals: Score free deals from Buffalo Wild Wings, 7-Eleven, Wingstop, Hooters, and more
4 outletsSalem police arrest 2 on drug charges after traffic stop
3 outletsWall Street trades mixed as global tech softness weighs and earnings take center stage
3 outletsIOS 26.6, macOS 26.6 and the rest are out, addressing security fixes